Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: The PreCARA study by Smeele, H.T.W. (Hieronymus T.W.) et al.
  1Smeele HTW, et al. Ann Rheum Dis 2021;0:1–6. doi:10.1136/annrheumdis-2020-219547
Rheumatoid arthritis
CLINICAL SCIENCE
Modern treatment approach results in low disease 
activity in 90% of pregnant rheumatoid arthritis 
patients: the PreCARA study
Hieronymus TW Smeele   , Esther Röder, Hetty M Wintjes, 
Laura JC Kranenburg- van Koppen, Johanna MW Hazes, Radboud JEM Dolhain
To cite: Smeele HTW, 
Röder E, Wintjes HM, et al. 
Ann Rheum Dis Epub ahead 
of print: [please include Day 
Month Year]. doi:10.1136/
annrheumdis-2020-219547
Handling editor Josef S 
Smolen
 ► Prepublication history 
and additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
annrheumdis- 2020- 219547).
Rheumatology, Erasmus MC, 
Rotterdam, The Netherlands
Correspondence to
Hieronymus TW Smeele, 
Erasmus MC, Rotterdam 3015 
GD, Netherlands;  
 h. smeele@ erasmusmc. nl
Received 18 November 2020
Revised 28 January 2021
Accepted 4 February 2021
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Objectives In patients with rheumatoid arthritis (RA), 
high disease activity impairs fertility outcomes and 
increases the risk of adverse pregnancy outcomes. The 
aim of this study was to determine the feasibility of a 
modern treatment approach, including treat- to- target 
(T2T) and the prescription of tumour necrosis factor 
(TNF) inhibitors, in patients with RA with a wish to 
conceive or who are pregnant.
Methods Patients were derived from the Preconception 
Counseling in Active RA (PreCARA) cohort. Patients 
with a wish to conceive or who are pregnant were 
treated according to a modified T2T approach, in which 
the obvious restrictions of pregnancy were taken into 
account. Results of the PreCARA study were compared 
with results of the Pregnancy- induced Amelioration of 
Rheumatoid Arthritis (PARA) study, a historic reference 
cohort on RA during pregnancy. Patients in the PARA 
cohort were treated according to the standards of that 
time (2002–2010). Differences in disease activity over 
time between the two cohorts were tested using a linear 
mixed model.
Results 309 patients with RA were included in the 
PreCARA study, 188 children were born. 47.3% of 
the patients used a TNF inhibitor at any time during 
pregnancy. Mean disease activity over time in the 
PreCARA cohort was lower than in the reference cohort 
(p<0.001). In the PreCARA cohort, 75.4% of the 
patients were in low disease activity (LDA) or remission 
before pregnancy increasing to 90.4% in the third 
trimester, whereas in the PARA cohort, these percentages 
were 33.2% and 47.3%, respectively.
Conclusions This first study on a modern treatment 
approach in pregnant patients with RA shows that LDA 
and remission are an attainable goal during pregnancy, 
with 90.4% of patients achieving this in the third 
trimester.
INTRODUCTION
Rheumatoid arthritis (RA) impairs fertility and 
pregnancy outcomes.1 High disease activity in 
patients with RA is associated with a prolonged time 
to pregnancy2 and is an independent risk factor for 
lower birth weight.3
Over the last decades, the treatment of RA has 
evolved: early diagnosis, immediate initiation of 
disease- modifying antirheumatic drugs (DMARDs), 
several new approved drugs and a treat- to- target 
(T2T) approach aiming for remission have resulted 
in better outcomes for patients.4–6 All of these 
developments are fundamental aspects of both the 
European League Against Rheumatism (EULAR) 
and the American College of Rheumatology (ACR) 
treatment guidelines.7 8
Tumour necrosis factor (TNF) inhibitors have 
revolutionised the treatment in RA. Treatment 
with TNF inhibitors and/or a combination of 
DMARDs are considered key elements of a T2T 
approach.5 9 Most TNF inhibitors are considered 
safe during pregnancy,10 11 resulting in the Euro-
pean Medicines Agency (EMA) advising to use 
certolizumab pegol if clinically needed during preg-
nancy and adalimumab, etanercept and infliximab 
if clearly needed during pregnancy.12 A drawback 
of prescribing TNF inhibitors during pregnancy is 
active transport of these biologics over the placenta 
into the fetal circulation. This occurs as early as 
week 18 of gestation.1 Therefore, the EULAR 
points to consider and ACR guidelines condition-
ally advise to discontinue treatment with most TNF 
inhibitors before the third trimester of pregnancy. 
These guidelines advise that certolizumab pegol can 
Key messages
What is already known about this subject?
 ► In patients with rheumatoid arthritis (RA), high 
disease activity is associated with a prolonged 
time to pregnancy and is an independent risk 
factor for lower birth weight of the offspring.
 ► Tumour necrosis factor (TNF) inhibitors are 
considered safe during pregnancy; however, 
it is not known how many patients require 
treatment with TNF inhibitors during pregnancy.
What does this study add?
 ► In this first study on a modern treatment 
approach during pregnancy, we showed that 
low disease activity (LDA) and remission are a 
feasible goal, with 90.4% of the patients in LDA 
in the third trimester of pregnancy.
How might this impact on clinical practice or 
future developments?
 ► In patients with RA with a wish to conceive or 
who are pregnant, clinicians should strive for 
remission or LDA.
 ► The effect of a modern treatment approach on 
fertility outcomes and pregnancy outcomes 
should be the focus of further studies.
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be continued throughout pregnancy.10 13 To date, the effect of 
stopping TNF inhibitors during pregnancy on disease activity 
is not well established, and what treatment strategy should be 
followed after stopping TNF inhibitors during pregnancy is 
unknown.
The efficacy of T2T was demonstrated in previous studies; 
however, whether this approach is feasible in pregnant patients 
with RA is unknown. The primary aim of our study was to eval-
uate the feasibility of a modified T2T approach aiming for remis-
sion or low disease activity (LDA) in patients with RA with a 
wish to conceive or who are pregnant. The secondary aims were 
to determine the percentage of patients that require treatment 
with TNF inhibitors during pregnancy, and to investigate the 
effect of stopping TNF inhibitors during pregnancy on disease 
activity.
METHODS
Patient population and data collection
Patients were derived from the Preconception Counseling 
in Active RA (PreCARA) cohort (first inclusion 2011). The 
PreCARA cohort is an ongoing, prospective cohort study on 
inflammatory rheumatic diseases and pregnancy. Available data 
up to 1 October 2020 was used for analysis. The PreCARA study 
is performed in one tertiary referral hospital (Erasmus MC, 
Rotterdam) and registered on  clinicaltrials. gov with reference 
number NCT01345071. For the current analysis, patients with 
RA who delivered and who had at least one visit post partum 
were used.
Patients were preferably included in the PreCARA study 
before they got pregnant. Study visits were scheduled every 3 
months before conception, during each trimester, and at 6, 12 
and 26 weeks post partum. At every visit, patients underwent 
joint examination, filled in questionnaires, blood was drawn and 
data on disease activity and frequencies and dosages of conven-
tional synthetic DMARDs (csDMARDs) and biologic DMARDs 
(bDMARDs) were collected. Information on relevant medical 
history and previous medication use were collected at inclusion.
PreCARA treatment protocol
Patients in the PreCARA cohort were treated according to a 
modified T2T approach aimed at remission. In this protocol, the 
obvious restrictions of pregnancy, previous response on treat-
ment, previous experienced side effects and patients preference 
were taken into account. Treatment was, if needed, intensified 
according to the T2T treatment approach at every study visit. In 
the PreCARA protocol, first, sulfasalazine and/or hydroxychlo-
roquine were started. Followed by the addition of prednisone 
(preferably in a maximum daily dosage of 7.5 mg) and/or a TNF 
inhibitor, preferably certolizumab pegol. Patients were allowed 
to get pregnant using the TNF inhibitor on which they enrolled 
in the cohort. TNF inhibitors were stopped during pregnancy at 
the gestational age as advised by the EULAR,10 and a switch to 
certolizumab pegol or prednisone was considered.
Data analysis
Disease activity was calculated using the Disease Activity Score 
with three variables: 28 swollen and tender joint count and C 
reactive protein (CRP) (DAS28CRP).14 15 We stratified disease 
activity states according to recommendations of the EULAR: 
remission (DAS28CRP≤2.6), LDA (2.6<DAS28CRP≤3.2), 
intermediate disease activity (3.2<DAS28CRP≤5.1) and high 
disease activity (DAS28CRP>5.1).16
In line with previous literature, we assessed increase in disease 
activity between 6 and 12 weeks post partum based on the 
‘reversed’ EULAR response criteria.17
Results of the PreCARA study were compared with the results 
of the Pregnancy- induced Amelioration of Rheumatoid Arthritis 
(PARA) study,17 18 a historic reference cohort on RA during preg-
nancy with a similar study design (inclusion 2002–2010). Patients 
in the PARA cohort were visited at home and were treated by 
their own rheumatologist according to the standards of that 
time for pregnancy, mainly using sulfasalazine, prednisone or no 
medication. Treatment in this time period was characterised by 
cautious approach due to insufficient information with regard 
to breast feeding, gonadotoxic effects and long- term effects in 
children exposed to immunosuppressive drugs in utero.19
Statistical analysis
Descriptive statistics are presented as numbers (n) and percent-
ages (%). Values are given as mean±SD or median±IQR. We 
tested categorical data using χ2 and Fisher’s exact tests, contin-
uous data using (paired) t- test, analysis of variance and Wilcoxon 
rank. A two- sided p value of <0.05 was considered significant.
Differences in disease activity over time between the cohorts 
were tested using linear mixed models with unstructured covari-
ance and random variation within individuals and between indi-
viduals. Subgroup analysis for the disease course over time for the 
use of TNF inhibitors during pregnancy is performed by using 
linear mixed models with unstructured covariance and random 
variation within individuals and between individuals. Patients 
who used a TNF inhibitor at any point during pregnancy were 
considered TNF inhibitor users during pregnancy. All statistical 
analyses were performed using Stata V.15 (StataCorp- LP).
Ethics
This study was approved by the Erasmus MC ethics review 
board in compliance with Declaration of Helsinki. All patients 
gave their informed consent.
Patient and public involvement
Patients were involved in the design of the cohorts. We obtained 
input from patients in the design of the questionnaires, cohort 
materials and cohort management. We carefully assessed the 
burden on participating patients. We intend to share the results 
to participating patients and will appropriately disseminate the 
results.
RESULTS
A total of 587 patients with an inflammatory rheumatic disease, 
of which 309 women had RA, were included in the PreCARA 
cohort. 188 children were born (4 twins). A detailed descrip-
tion of the demographics of these women and a description of 
patients in the PARA cohort are given in table 1.
Medication use during pregnancy
Table 2 shows the medication used in the PreCARA cohort. 
Eleven patients (6.0%) did not use any DMARDs during preg-
nancy. Sulfasalazine, hydroxychloroquine, prednisone and 
certolizumab pegol were the most commonly used DMARDs. 
The median daily dosage of prednisone in the third trimester of 
pregnancy was 5 mg (IQR 5–7.5 mg), 19.0% of the patients used 
a dosage of >7.5 mg at at least one timepoint during pregnancy. 
The median daily dosage, for the same period, of hydroxychlo-
roquine was 200 mg (IQR 200–400 mg) and of sulfasalazine was 
2000 mg (IQR 1000–2000 mg).
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TNF-inhibitor use during pregnancy
Eighty- seven patients (47.3%) used a TNF inhibitor at any time 
during pregnancy. The most frequently used TNF inhibitor 
was certolizumab pegol. A total of 26 patients stopped treat-
ment with a TNF inhibitor during pregnancy: adalimumab n=4, 
infliximab n=7, etanercept n=13, certolizumab pegol n=4. 
After stopping their TNF, inhibitor, 17 patients (65.4%) used 
prednisone in the third trimester of pregnancy. Thirteen patients 
with RA switched their type of TNF inhibitor during pregnancy: 
switch from adalimumab to certolizumab pegol, n=4; switch 
from etanercept to certolizumab pegol n=5; switch from inflix-
imab to certolizumab pegol n=4. The median number of weeks 
of gestation when treatment with infliximab was stopped was 
15.3 weeks (IQR 12.7–20.3 weeks), for adalimumab this was 
18.4 weeks (IQR 16.9–19.5 weeks), for etanercept 23.4 weeks 
(IQR 9.9–26.9 weeks) and for certolizumab pegol 35.6 weeks 
(IQR 26.3–37.4 weeks).
In the third trimester of pregnancy, TNF inhibitors (number 
of patients that used TNF inhibitors in the third trimester=56) 
were in 62.5% of the patients combined with sulfasalazine, in 
46.4% of the patients with hydroxychloroquine and in 35.7% 
with prednisone. Twenty- five patients (44.6%) used both sulfas-
alazine and hydroxychloroquine combined with their TNF 
inhibitor (with or without prednisone). In patients that did not 
use a TNF inhibitor (n=116) in the third trimester, sulfasalazine, 
hydroxychloroquine and prednisone were frequently used 
in combination. Further, 30.2% of the patients (n=35) used 
sulfasalazine, hydroxychloroquine and prednisone in combina-
tion, while 32.8% of the patients (n=38) used sulfasalazine and 
hydroxychloroquine without prednisone.
Medication use in the historic reference cohort
In this cohort of patients, 41.2% did not use any DMARDs 
during pregnancy (table 3). Patients in the PARA cohort were 
usually on stable medication: 85% of the patients used the 
same medication in the first trimester of pregnancy compared 
with the prepregnancy visit. Prednisone and sulfasalazine were 
most frequently prescribed during pregnancy. The median daily 
dosage of prednisone was 7.5 mg (IQR 5–10 mg), 70.6% of 
the patients used a dosage of >7.5 mg at at least one timepoint 
during pregnancy. Sulfasalazine was used by 63 (25.7%) patients 
in the third trimester, in 2 (3.2%) patients sulfasalazine was 
combined with hydroxychloroquine and in 23 (36.5%) patients 
with prednisone.
Disease activity during pregnancy
Disease activity did not change during pregnancy and post-
partum in the PreCARA- cohort (figure 1).
Table 1 Clinical and demographic features of patients with rheumatoid arthritis included in the PreCARA cohort (n=184) and PARA cohort 
(n=253) that were used for the current data analysis
Variable PreCARA cohort PARA cohort P value
Mean age at delivery, years (SD) 32.8 (3.9) 32.7 (3.8) 0.88
Median disease duration at first visit, years (IQR) 6.8 (3.7–10.7) 4.9 (2.2–9.7) 0.009
Erosive disease, n (%) 52 (28.3) 161 (63.7) <0.001
Rheumatoid factor positive and/or ACPA positive, n (%) 164 (89.1) 176 (71.8) <0.001
Nulliparity, n (%) 81 (44.0) 126 (49.8) 0.23
Education level, years of education (SD) 15.9 (3.5) 15.0 (3.0) 0.02
Number of different DMARDs prescribed prior to inclusion in the cohort (IQR) 3 (2–4) 2 (1–3) <0.001
Number of different csDMARDs prescribed prior to inclusion in the cohort (IQR) 2 (2–3) 2 (1–2) <0.001
Number of different bDMARDs prescribed prior to inclusion in the cohort (IQR) 1 (0–2) 0 (0–0) <0.001
ACPA, anti- citrullinated protein antibody; bDMARDs, biologic disease- modifying antirheumatic drugs; csDMARDs, conventional synthetic disease- modifying antirheumatic drugs; 
DMARDs, disease- modifying antirheumatic drugs.































Methotrexate 2 (1.7) 0 0 0 27 (15.9) 34 (22.2) 31 (24.8)
Leflunomide 0 0 0 0 1 (0.6) 2 (1.3) 3 (2.4)
Hydroxychloroquine 77 (66.4) 96 (57.5) 94 (54.0) 93 (54.1) 97 (57.1) 88 (57.5) 70 (56.0)
Sulfasalazine 76 (65.6) 103 (61.7) 104 (59.8) 103 (59.8) 104 (61.2) 95 (62.1) 79 (63.2)
Prednisone 53 (45.7) 69 (41.3) 67 (38.5) 72 (41.9) 67 (39.4) 60 (39.2) 46 (36.8)
Azathioprine 1 (0.9) 3 (1.8) 3 (1.7) 3 (1.7) 1 (0.6) 2 (1.3) 1 (0.8)
Certolizumab pegol 31 (26.7) 38 (22.8) 48 (27.6) 50 (29.1) 47 (27.7) 46 (30.1) 38 (30.4)
Adalimumab 8 (6.9) 8 (4.8) 0 0 5 (2.9) 6 (3.9) 7 (5.6)
Etanercept 19 (16.4) 20 (12.0) 19 (10.9) 6 (3.5) 19 (11.2) 22 (14.4) 16 (12.8)
Infliximab 11 (9.5) 11 (6.6) 4 (2.3) 0 1 (0.6) 2 (1.3) 1 (0.8)
Tocilizumab 2 (1.7) 0 0 0 4 (2.4) 4 (2.6) 6 (4.8)
Golimumab 0 0 0 0 0 0 1 (0.8)
Abatacept 0 0 0 0 1 (0.6) 2 (1.3) 2 (1.6)
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Mean DAS28CRP before pregnancy in the historic reference 
cohort was 3.73 (SD 1.18) and decreased during pregnancy 
to DAS28CRP 3.35 (SD 1.12) in the third trimester. Disease 
activity increased in the postpartum period, the highest observed 
DAS28CRP 3.78 was at 12 weeks post partum (SD 1.28) 
(figure 1).
Disease activity over time in the PreCARA cohort was statis-
tically significantly lower than in the historic reference cohort 
(p<0.001). Also, mean disease activity at every different time-
point in the PreCARA cohort was statistically significant lower 
(p<0.001).
The percentage of patients in remission or LDA in the 
PreCARA cohort was significantly higher at all timepoints during 
follow- up compared with the PARA cohort (p<0.001) (figure 2). 
In the PreCARA cohort, the total number of patients in remis-
sion and LDA increased from 64.8% and 75.4% at inclusion 
to 76.1% and 90.4%, respectively, in the third trimester. The 
number of patients in remission remained stable post partum. 
The percentage of patients in different disease activity states was 
different between the PreCARA cohort and the PARA cohort at 
all timepoints (p<0.001) (figure 2).
TNF-inhibitor use and disease activity during pregnancy
Stratified analysis showed no statistically significant difference 
in disease activity in the third trimester of pregnancy between 
patients that switched their TNF inhibitor to certolizumab pegol 
during pregnancy (n=13, DAS28CRP 2.17 (SD 0.73)) versus 
patients that stopped their TNF inhibitor and used prednisone 
(n=17, DAS28CRP 2.63 (SD 0.69)) versus patients that used 
certolizumab pegol throughout pregnancy (n=30, DAS28CRP 
2.18 (SD 0.63)), versus patients that stopped their TNF inhib-
itor and did not use certolizumab pegol nor prednisone (n=8, 
DAS28CRP 2.23 (SD 0.67)), p=0.13.
Disease activity over time did not differ between patients who 
used a TNF inhibitor during pregnancy (any use during preg-
nancy) and patients who did not (p=0.14) (online supplemental 
figure 1).
Disease activity increase post partum
Not one patient in the PreCARA cohort experienced a severe 
increase in disease activity post partum, 12.2% of the patients in 
this cohort experienced a moderate increase. These rates were 
5.7% (vs PreCARA cohort, p=0.01) and 21.0%(vs PreCARA 
cohort, p=0.18) in the PARA cohort, respectively.
































Methotrexate 0 0 0 0 45 (18.8) 73 (30.4) 89 (40.0)
Leflunomide 0 0 0 0 0 3 (1.3) 4 (1.8)
Hydroxychloroquine 8 (6.5) 5 (2.3) 5 (2.2) 4 (1.6) 10 (4.2) 19 (7.9) 18 (8.1)
Sulfasalazine 42 (33.9) 61 (28.6) 65 (28.0) 63 (25.7) 64 (26.8) 73 (30.4) 70 (31.5)
Prednisone 52 (41.9) 80 (37.6) 87 (37.5) 87 (35.5) 85 (35.6) 89 (37.1) 78 (35.1)
Azathioprine 2 (1.6) 1 (0.5) 1 (0.4) 1 (0.4) 3 (1.3) 2 (0.8) 2 (0.9)
Adalimumab 0 0 0 0 5 (2.1) 7 (2.9) 12 (5.4)
Infliximab 0 0 0 0 1 (0.4) 2 (0.8) 3 (1.4)
Etanercept 0 0 0 0 7 (2.9) 14 (5.8) 13 (5.9)
The medication that is not listed in this table was not prescribed during this study period.
Figure 1 DAS28CRP (mean, SD) scores over time for the PreCARA 
cohort (modern treatment approach cohort) and the PARA cohort 
(historic reference cohort). The x-axis displays specific timepoints before, 
during and after pregnancy, and the y-axis represents mean (SD) disease 
activity. Mean disease activity over time in the PreCARA cohort was 
lower than in the reference cohort (p<0.001).
Figure 2 Bar charts showing disease activity states DAS28CRP scores 
for the PARA cohort (historic reference cohort) (A) and the PreCARA 
cohort (modern treatment approach cohort) (B). The x-axis displays the 
specific timepoints before, during and after pregnancy, and the y-axis 
shows the percentage of patients in the different disease activity states. 
The percentage of patients in moderate or high disease activity was 
higher at all timepoints in the historic reference cohort compared with 
the modern treatment approach cohort (p<0.001).
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DISCUSSION
Until recently, rheumatologists assumed that almost all patients with 
RA reach a state of remission during pregnancy independent of treat-
ment; however, more literature shows that over half of the patients 
still has active disease during pregnancy.1 17 20 This highlighted the 
need for improved care. Our study was the first to evaluate a T2T 
approach, with the use of TNF inhibitors, low dose prednisone and 
a combination of DMARDs, in patients with RA with a wish to 
conceive or get pregnant. Our results show that entering pregnancy 
in LDA or remission, as advised by ACR guidelines, is attainable 
when applying T2T. Over 80% of the patients in our study was in 
LDA at their last visit before pregnancy. Moreover, we showed that 
applying a T2T approach results in LDA during pregnancy and post 
partum in a vast majority of patients with RA.
Half of the patients in our study were able to get in LDA or remis-
sion using only csDMARDs or prednisone. In a large percentage 
of the patients, csDMARDs were prescribed in combination. The 
percentage of patients on prednisone during pregnancy was compa-
rable between our modern treatment approach cohort and the 
historic reference cohort. However, the dosage of prednisone that 
was used during pregnancy was considerably lower in the modern 
treatment approach cohort. In this cohort, it was chosen to pref-
erably prescribe a maximum dosage of 7.5 mg to limit the risk of 
fertility problems, premature birth, gestational diabetes and high 
blood pressure since higher doses of prednisone are associated with 
these complications during pregnancy.1 21
We showed that TNF inhibitors were efficacious during preg-
nancy, no significant difference in disease activity over time between 
patients that used a TNF inhibitor during pregnancy and patients 
who used csDMARDs were observed. Patients that were included in 
our cohort were allowed to get pregnant using their own TNF inhib-
itor in order to prevent an increase in disease activity by switching 
therapy. We did, however, observe a larger percentage of patients 
using certolizumab pegol at inclusion in our cohort (21.2%) than 
one can expect from the usual Dutch RA patient population.22 This 
could be caused by a switch to certolizumab pegol already before 
referral to our specialised clinic, since literature shows no to minimal 
placental transfer of certolizumab pegol during pregnancy.23 During 
pregnancy, TNF inhibitors were stopped at the gestational age 
advised by the EULAR. Due to reports on high bioavailability of 
infliximab during pregnancy, it was later chosen to stop infliximab 
preferably before week 16 of gestation in line with British Society of 
Rheumatology guidelines.24 After stopping a TNF inhibitor during 
pregnancy, a switch to certolizumab pegol or prednisone was consid-
ered to prevent a possible increase in disease activity. Based on expert 
opinion, certolizumab pegol was arbitrarily stopped at 38 weeks of 
gestational age in order to minimise maternal infectious compli-
cations during delivery. This expert opinion was formed based 
on guidelines to withhold treatment with a TNF inhibitor before 
surgery.25 TNF inhibitors could be restarted 1 week after a vaginal 
delivery and 2 weeks after a caesarean section. After delivery, there 
was no specific preference for one certain TNF inhibitor. However, 
patients got counselling on breast feeding and many preferred certoli-
zumab pegol due to its robust pharmacokinetic data for use during 
breast feeding.26 According to guidelines, no woman that breast fed 
used methotrexate. Children that were exposed to TNF inhibitors 
in utero were vaccinated in line with the Dutch national vaccination 
policy, in which the first live inactivated vaccine is administered at 14 
months. No exceptions for any of the TNF inhibitors were made.
We observed, based on a low number of observations, no statis-
tically significant difference in disease activity between patients that 
switched TNF- inhibitor treatment during pregnancy and patients 
that stopped TNF- inhibitor treatment all together. However, this 
observation is confounded by indication: TNF inhibitors were 
stopped only in those patients in complete remission after careful 
consideration of the treating physician and in consultation with the 
patient. Although TNF inhibitors were stopped, many patients used 
other medication like prednisone. These results show that physi-
cians are able to distinguish between those patients that have calm 
disease during pregnancy in which TNF inhibitors can be stopped 
and patients that, despite having LDA, do require a switch in medi-
cation during pregnancy to prevent an increase in disease activity. 
Our results should not be interpreted as if TNF inhibitors can be 
stopped during pregnancy without an increased risk of increase in 
disease activity.
Patients with RA have an increased risk of a flare in disease activity 
after delivery,1 20 not one patient in our modern treatment approach 
cohort experienced a severe increase in disease activity post partum. 
In the absence of well- defined criteria, we used criteria based on the 
‘reversed’ EULAR response criteria. However, we should note that 
RA flares are complex, and comprehend more than an increase in 
disease activity as measured by a physician.27
Also, mean disease activity post partum was not different from 
mean disease activity during pregnancy. This indicates that applying 
T2T and an immediate restart of medication after delivery may help 
to prevent an increase in disease activity post partum.
The PreCARA study was designed as an observational study 
reflecting daily clinical practice in a specialised centre for arthritis 
and systemic autoimmune disorders and pregnancy. The selection 
of patients was therefore different from randomised controlled trials 
(RCTs), like the TICORA trial,6 on which the most evidence on 
T2T is based. Comparing our results with the results of these RCTs 
might not be appropriate. In previously published studies on T2T in 
daily clinical practice, the percentage of patients in remission after 
an extensive follow- up period varies between 52% and 62.6%.28 29 
The percentage of patients in remission in our study increased from 
62.8% at inclusion in the cohort to 74.4% in the third trimester of 
pregnancy. And although our study cannot be compared directly to 
these studies, it underscores that in pregnant patients with RA, a T2T 
approach is feasible too.
Some limitations of our study need to be considered. We 
compared the results of our modern treatment approach cohort with 
the results of a historic cohort. Patient characteristics in this historic 
cohort are slightly different compared with the current patient popu-
lation. Second, our study could have suffered from selection bias. 
Our study was performed in one tertiary referral centre, which could 
have resulted in an over- representation of patients with more severe 
disease. The significant difference in percentage of patients that had 
RF or anti- citrullinated protein antibody (ACPA) antibodies in the 
PreCARA cohort could indicate that this type of bias has occurred. 
Yet, we showed that even in these patients with more severe disease, 
LDA during pregnancy is attainable. Furthermore, based on the 
nature of our study, it was impossible to show that either T2T or new 
targeted therapies such as TNF inhibitors or combination therapy, 
or all were responsible for the improved disease outcomes during 
pregnancy.
We presented in our study only those patients who got pregnant. 
It is reasonable to speculate that there is an over- representation of 
patients in LDA or remission in the current study, since active disease 
is associated with a longer time to pregnancy.2 However, for those 
patients that did not get pregnant, the mean DAS28CRP of all visits 
during their wish to conceive was 2.36 (SD 1.00). Therefore, we 
conclude that selection bias based on disease activity is not a relevant 
factor in our study.
Our study has several strengths. This is the first study to prospec-
tively collect results of a T2T approach in a large cohort of pregnant 
patients with RA. And, the study was performed in only one tertiary 
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referral hospital, which limited the variation on management of the 
disease between healthcare professionals. Moreover, the results of 
the current cohort will allow us to study the effect of T2T and TNF 
inhibitors on fertility outcomes and pregnancy outcomes in patients 
with RA in future studies.
The findings of our study should be applied in daily clinical 
practice. We advise clinicians to apply a T2T approach, including 
prescribing TNF inhibitors, in all patients with a wish to conceive and 
during pregnancy. We showed that patients can get pregnant with the 
TNF inhibitor they already used before pregnancy, and TNF inhibi-
tors can be switched during pregnancy, without an increase in disease 
activity. Moreover, we advise pregnancy counselling and regular 
visits during pregnancy and post partum like performed in our 
specialised hospital. This extra care will contribute to the improved 
disease outcomes like we observed in our study.
In conclusion, we showed that a modern treatment approach 
results in LDA or remission in 90% of pregnant patients with RA. 
Therefore, LDA or remission should also be strived for in this group 
of patients, despite the obvious restrictions on medication use during 
pregnancy.
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